Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
The ESMO ESCAT classification can be used to guide in the selection of patients with head and neck squamous cell carcinoma for targeted treatment strategies in clinical studies
Extension concerns the treatment of classical Hodgkin lymphoma
Efficacy was demonstrated in the VISION study
Application concerned the use in combination with platinum-based therapy in previously untreated metastatic urothelial cancer
It is intended for the treatment of relapsed and refractory multiple myeloma
Results from a cross-sectional survey in France
It is intended for second-line treatment of advanced cholangiocarcinoma with a FGFR2 fusion or rearrangement
Evidence for efficacy is based on the results from the CHECKMATE-9ER study
Evidence for efficacy is based on the results from the ANDROMEDA study
The Cancer and Aging Research Group-Breast Cancer score was developed and validated to predict grade 3-5 toxicity in elderly patients with stage I-III disease
Evidence for efficacy is based on the results from the DESTINY-Gastric01 study
The safety and efficacy of crizotinib is not established in older adults with same disease
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
